Enterprise HL7 / FHIR Terminology Engine
Universal Clinical Codes & Terminology Search
Search, verify, and inspect standardized LOINC, SNOMED CT, ICD-10-CM, RxNorm, and CPT clinical codes with native HL7 FHIR R4 resource mappings.
Showing 20 of 23669 codes
Per page:
Need to map or validate codes in bulk?
Cross-reference up to 1,000 ICD-10, LOINC, and CPT records simultaneously in memory with our free utility.
| Code Value | Display Description | Code System & OID | FHIR Resource | Category | Status | Actions |
|---|---|---|---|---|---|---|
|
O90.6
|
Postpartum mood disturbance
|
ICD-10-CM
2.16.840.1.113883.6.90
|
Condition | Complications predominantly related to the puerperium | Active |
|
|
P00.82
|
Newborn affected by (positive) maternal group B streptococcus (GBS) colonization
|
ICD-10-CM
2.16.840.1.113883.6.90
|
Condition | Newborn affected by maternal factors and by complications of pregnancy, labor, and delivery | Active |
|
|
P03.1
|
Newborn affected by other malpresentation malposition and disproportion during labor and delivery
|
ICD-10-CM
2.16.840.1.113883.6.90
|
Condition | Newborn affected by maternal factors and by complications of pregnancy, labor, and delivery | Active |
|
|
P04.6
|
Newborn affected by maternal exposure to environmental chemical substances
|
ICD-10-CM
2.16.840.1.113883.6.90
|
Condition | Newborn affected by maternal factors and by complications of pregnancy, labor, and delivery | Active |
|
|
P08.21
|
Post-term newborn
|
ICD-10-CM
2.16.840.1.113883.6.90
|
Condition | Disorders of newborn related to length of gestation and fetal growth | Active |
|
|
P52.6
|
Cerebellar (nontraumatic) and posterior fossa hemorrhage of newborn
|
ICD-10-CM
2.16.840.1.113883.6.90
|
Condition | Hemorrhagic and hematological disorders of newborn | Active |
|
|
P6
|
A declared brain-dead patient whose organs are being removed for donor purposes
|
HCPCS
2.16.840.1.113883.6.14
|
Procedures | Procedures | Active |
|
|
P96.81
|
Exposure to (parental) (environmental) tobacco smoke in the perinatal period
|
ICD-10-CM
2.16.840.1.113883.6.90
|
Condition | Other disorders originating in the perinatal period | Active |
|
|
PI
|
Positron emission tomography (pet) or pet/computed tomography (ct) to inform the initial treatment strategy of tumors that are biopsy proven or strongly suspected of being cancerous based on other diagnostic testing
|
HCPCS
2.16.840.1.113883.6.14
|
Procedures | Procedures | Active |
|
|
PM
|
Post mortem
|
HCPCS
2.16.840.1.113883.6.14
|
Procedures | Procedures | Active |
|
|
PS
|
Positron emission tomography (pet) or pet/computed tomography (ct) to inform the subsequent treatment strategy of cancerous tumors when the beneficiary's treating physician determines that the pet study is needed to inform subsequent anti-tumor strategy
|
HCPCS
2.16.840.1.113883.6.14
|
Procedures | Procedures | Active |
|
|
Q0115
|
Post-coital direct qualitative examinations of vaginal or cervical mucous
|
HCPCS
2.16.840.1.113883.6.14
|
Procedures | Procedures | Active |
|
|
Q0220
|
Injection tixagevimab and cilgavimab for the pre-exposure prophylaxis only for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s) 300 mg
|
HCPCS
2.16.840.1.113883.6.14
|
Procedures | Procedures | Active |
|
|
Q0221
|
Injection tixagevimab and cilgavimab for the pre-exposure prophylaxis only for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s) 600 mg
|
HCPCS
2.16.840.1.113883.6.14
|
Procedures | Procedures | Active |
|
|
Q0224
|
Injection pemivibart for the pre-exposure prophylaxis only for certain adults and adolescents (12 years of age and older weighing at least 40 kg) with no known sars-cov-2 exposure and who either have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and are unlikely to mount an adequate immune response to covid-19 vaccination 4500 mg
|
HCPCS
2.16.840.1.113883.6.14
|
Procedures | Procedures | Active |
|
|
Q0235
|
Injection monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19 for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen non-invasive or invasive mechanical ventilation or extracorporeal membrane oxygenation (ecmo) only not otherwise classified 1 mg
|
HCPCS
2.16.840.1.113883.6.14
|
Procedures | Procedures | Active |
|
|
Q0516
|
Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug per 30-days
|
HCPCS
2.16.840.1.113883.6.14
|
Procedures | Procedures | Active |
|
|
Q0517
|
Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug per 60-days
|
HCPCS
2.16.840.1.113883.6.14
|
Procedures | Procedures | Active |
|
|
Q0518
|
Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug per 90-days
|
HCPCS
2.16.840.1.113883.6.14
|
Procedures | Procedures | Active |
|
|
Q0519
|
Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription injectable drug per 30-days
|
HCPCS
2.16.840.1.113883.6.14
|
Procedures | Procedures | Active |
|
Healthcare Terminology & FHIR R4 Interoperability
Standardized coding guidelines governed by CodesForMD
In HL7 FHIR R4, discrete clinical findings and laboratory measurements are encapsulated inside
Observation resources. Diagnostic terms and problem list entries are represented within Condition resources, while surgical and therapeutic acts map to Procedure. CodesForMD adheres to official US Core and International FHIR Implementation Guides.
An OID is an internationally standardized dotted-decimal identifier (e.g.
2.16.840.1.113883.6.1 for LOINC) registered with HL7 and ISO. OIDs ensure unambiguous identification of terminology authorities when exchanging clinical messages across heterogeneous EHR, LIS, and PACS systems.
Yes. You can visit our platform's administrative ingestion and export engine or contact our team to obtain batch files of standardized codes.